UK markets closed

Ventyx Biosciences, Inc. (VTYX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.8800+0.0100 (+0.35%)
At close: 04:00PM EDT
2.8400 -0.04 (-1.39%)
After hours: 04:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.8700
Open2.8400
Bid2.8700 x 200
Ask2.9000 x 300
Day's range2.8310 - 2.9926
52-week range1.8650 - 40.5800
Volume443,479
Avg. volume1,172,801
Market cap203.038M
Beta (5Y monthly)0.58
PE ratio (TTM)N/A
EPS (TTM)-3.2400
Earnings date25 Mar 2024 - 29 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.80
  • GlobeNewswire

    Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

    VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that

  • GlobeNewswire

    Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

    SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: Event: UBS Obesity Therapeutics DayLocation: VirtualDate: Thursday, May 23, 2024Time: 12:00-12:30 PM ET Event: Jefferies Glob

  • GlobeNewswire

    Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

    SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. “I am excited to welcome Matt to the Ventyx leadership team,” said Raju Mohan, Chief Executive Officer. “He brings a wealth of expertise to V